Evidence map›Paper›PMID 40227590›Full record

ArticleCancers2025

β-Catenin Drives the FOXC2-Mediated Epithelial-Mesenchymal Transition and Acquisition of Stem Cell Properties.

Maria Castaneda, Petra den Hollander, Steve Werden, Esmeralda Ramirez-Peña, Suhas V Vasaikar, Nick A Kuburich, Claire Gould, Rama Soundararajan, Sendurai A Mani

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. IRS2 as a driver and therapeutic target in brain metastases from colorectal cancer: a systematic review of mechanistic and translational evidence.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Pooled it
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Maria CastanedaDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Research Center, Houston, TX 77030, USA.
Petra den HollanderDepartment of Pathology and Laboratory Medicine, The Warren Alpert Medical School, Brown University, Providence, RI 02912, USA.ORCID 0000-0002-4272-1231
Steve WerdenDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Research Center, Houston, TX 77030, USA.
Esmeralda Ramirez-PeñaDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Research Center, Houston, TX 77030, USA.
Suhas V VasaikarDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Research Center, Houston, TX 77030, USA.
Nick A KuburichDepartment of Pathology and Laboratory Medicine, The Warren Alpert Medical School, Brown University, Providence, RI 02912, USA.ORCID 0000-0002-6720-9680
Claire GouldDepartment of Pathology and Laboratory Medicine, The Warren Alpert Medical School, Brown University, Providence, RI 02912, USA.ORCID 0000-0001-8264-0463
Rama SoundararajanDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Research Center, Houston, TX 77030, USA.ORCID 0000-0001-6976-3784
Sendurai A ManiDepartment of Pathology and Laboratory Medicine, The Warren Alpert Medical School, Brown University, Providence, RI 02912, USA.

Funding

Vimentin Phospho-Malleability is Critical for Maintaining Stemness and Metastatic PropertiesR01CA262106 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Sendurai Ayyavoo Mani · 2022 to 2026
$1.5M
Bowes Foundation NAJohn and Pat Tarantino Foundation NAMD Anderson IRG NANational Institute of Health 5T32CA217789-04National Institute of Health R01CA155243National Science Foundation 15-597-1605817National Science Foundation DMS-2245957NCI NIH HHS R01 CA262106Papitto Opportunity Connection NA
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

cancer stem cellsepithelial–mesenchymal transitionforkhead transcription factorsFOXC2triple-negative breast cancerβ-catenin signaling

Identifiers

PMID40227590
PMCPMC11987759

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.